The Board of Directors at their meeting held today, 19th June 2025 has approved the proposal to raising of funds by way of issuance of equity shares and / or eligible securities through ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudarshan Pharma Industries' Board of Directors, at a meeting held on 19th June 2025, approved a proposal to raise funds up to ₹350 Crores (or equivalent in foreign currency). The funds may be raised through equity shares and a wide range of eligible securities, including Foreign Currency Convertible Bonds (FCCBs), fully/partly convertible debentures, non-convertible debentures with warrants, and other instruments convertible into equity shares. The company may use one or more routes — public issue, preferential issue, qualified institutions placement (QIP), private placement, or a combination — in domestic and/or international markets, in one or more tranches. The proposal is subject to approval from regulatory authorities and shareholders at a general meeting.
This is a potential dilution event for existing shareholders as the company plans to issue fresh equity-linked securities worth up to ₹350 Crores. The final impact on share price will depend on the issue price, structure, and timing. Short-term share price may face pressure depending on pricing relative to market price, though the capital infusion could support business growth if used productively.